185 related articles for article (PubMed ID: 31401568)
21. Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.
Oberkirchner U; Linder KE; Zadrozny L; Olivry T
Vet Dermatol; 2010 Oct; 21(5):510-6. PubMed ID: 20500495
[TBL] [Abstract][Full Text] [Related]
22. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome.
Otto AI; Marschalko M; Zalatnai A; Toth M; Kovacs J; Harsing J; Tulassay Z; Karpati S
J Am Acad Dermatol; 2011 Aug; 65(2):458-459. PubMed ID: 21763589
[No Abstract] [Full Text] [Related]
23. Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases.
El Rassi Z; Partensky C; Valette PJ; Berger F; Chayvialle JA
Eur J Surg Oncol; 1998 Dec; 24(6):562-7. PubMed ID: 9870735
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract][Full Text] [Related]
25. Glucagonoma-related necrolytic migratory erythema.
Bosch-Amate X; Riera-Monroig J; Iranzo Fernández P
Med Clin (Barc); 2020 Nov; 155(9):418-419. PubMed ID: 31515063
[No Abstract] [Full Text] [Related]
26. [Malignant glucagonoma: an uncommon cause of new onset diabetes].
Guerrero Vázquez R; Oliva Rodríguez R; Cuenca Cuenca JI; Sánchez Alberdi F; Navarro González E
Endocrinol Nutr; 2011 Apr; 58(4):199-201. PubMed ID: 21334267
[No Abstract] [Full Text] [Related]
27. Effect of somatostatin in necrolytic migratory erythema of glucagonoma.
Elsborg L; Glenthøj A
Acta Med Scand; 1985; 218(2):245-9. PubMed ID: 2865872
[TBL] [Abstract][Full Text] [Related]
28. Delayed diagnosis of glucagonoma syndrome: a case report.
Huo J; Liu P; Chen X; Wu J; An J; Ren J
Int J Dermatol; 2016 Nov; 55(11):1272-1274. PubMed ID: 26679842
[No Abstract] [Full Text] [Related]
29. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome.
Remes-Troche JM; García-de-Acevedo B; Zuñiga-Varga J; Avila-Funes A; Orozco-Topete R
J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):591-5. PubMed ID: 15324403
[TBL] [Abstract][Full Text] [Related]
30. Glucagonoma syndrome with atypical necrolytic migratory erythema.
He S; Zeng W; Geng S; Jia J
Indian J Dermatol Venereol Leprol; 2021; 87(1):49-53. PubMed ID: 31368453
[TBL] [Abstract][Full Text] [Related]
31. Rapid resolution of necrolytic migratory erythema after glucagonoma resection.
Smith AP; Doolas A; Staren ED
J Surg Oncol; 1996 Apr; 61(4):306-9. PubMed ID: 8628004
[TBL] [Abstract][Full Text] [Related]
32. Necrolytic migratory erythema: a common cutaneous clue of uncommon syndromes.
Stavropoulos PG; Papafragkaki DK; Avgerinou G; Papafragkakis H; Katsavou A; Katsambas AD
Cutis; 2013 Nov; 92(5):E1-4. PubMed ID: 24343217
[No Abstract] [Full Text] [Related]
33. Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report.
Watt DG; Pandanaboyana S; Herrington CS; Tait IS
JOP; 2013 Sep; 14(5):510-4. PubMed ID: 24018597
[TBL] [Abstract][Full Text] [Related]
34. Necrolytic migratory erythema associated with alteration from predominantly gastrin-secreting to predominantly glucagon-secreting pancreatic neuroendocrine tumor.
Kido-Nakahara M; Nakahara T; Miki M; Igarashi H; Ito T; Furue M
Eur J Dermatol; 2014; 24(6):702-3. PubMed ID: 25333507
[No Abstract] [Full Text] [Related]
35. Necrolytic migratory erythema: an important sign of glucagonoma.
Cui M; Wang R; Liao Q
Postgrad Med J; 2021 Mar; 97(1145):199. PubMed ID: 32527759
[No Abstract] [Full Text] [Related]
36. [Necrolytic cutaneous erythema and pancreatic tumour: the glucagonoma].
Drematcheff S; Champetier de Ribes TL; Marty C; Sans N; Railhac JJ
J Radiol; 2004 Mar; 85(3):329-31. PubMed ID: 15192527
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration.
Santangelo WC; Unger RH; Orci L; Dueno MI; Popma JJ; Krejs GJ
Pancreas; 1986; 1(5):464-9. PubMed ID: 2882503
[TBL] [Abstract][Full Text] [Related]
38. Necrolytic migratory erythema as the only presenting sign of a glucagonoma.
Johnson SM; Smoller BR; Lamps LW; Horn TD
J Am Acad Dermatol; 2003 Aug; 49(2):325-8. PubMed ID: 12894090
[TBL] [Abstract][Full Text] [Related]
39. Necrolytic migratory erythema: first symptom of a glucagonoma. A case report.
Du Jardin P; Cools P; Van der Stighelen Y
Acta Chir Belg; 2004 Aug; 104(4):468-70. PubMed ID: 15469167
[TBL] [Abstract][Full Text] [Related]
40. Necrolytic Migratory Erythema Associated with a Glucagonoma.
Banerjee A; Shah SR
N Engl J Med; 2020 Aug; 383(6):e39. PubMed ID: 32757527
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
